In DepthBiomedicine

Cystic fibrosis foundation opens drug discovery lab

See allHide authors and affiliations

Science  16 Sep 2016:
Vol. 353, Issue 6305, pp. 1194-1195
DOI: 10.1126/science.353.6305.1194

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


The Cystic Fibrosis Foundation is once again breaking new ground. In 2000, with little beyond symptomatic relief available for the inherited, life-threatening condition, the Bethesda, Maryland–based foundation hired a biotech company to develop more effective treatments. The move, unprecedented for a disease advocacy organization, paid off in two new drugs, the first to target the molecular root of the disease. But there is still no cure, and cystic fibrosis patients continue to die—467 in the United States alone in 2014. So on 19 September, the foundation is setting another precedent by officially opening its own independent laboratory in Lexington, Massachusetts, to speed drug development, funded primarily from the success of the two drugs it helped bring to fruition.